Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine
Our analysis extends the spectrum of mutations emerging in PLWH receiving RPV. Additional phenotypic characterization of RPV-selected mutations is necessary to better understand their biological and possible clinical significance.
Authors
- Carole Seguin‐Devaux (ORCID: https://orcid.org/0000-0003-0636-5222)
- Maurizio Zazzi (ORCID: https://orcid.org/0000-0002-0344-6281)
- Perpétua Gómes (ORCID: https://orcid.org/0000-0003-3271-8255)
- Francesca Incardona (ORCID: https://orcid.org/0000-0002-7386-8551)
- Kaiming Tao (ORCID: https://orcid.org/0000-0001-8731-1271)
- Pavithra Nagarajan (ORCID: https://orcid.org/0000-0002-0036-9970)
- Robert W. Shafer (ORCID: https://orcid.org/0000-0003-2513-2643)
- Rolf Kaiser (ORCID: https://orcid.org/0000-0002-2640-2548)
- Giulia Di Teodoro (ORCID: https://orcid.org/0000-0002-0418-0067)
- Ana Abecasis (ORCID: https://orcid.org/0000-0002-3903-5265)
- Jinru Zhou
Institutions
- University of Siena (IT)
- University of Pisa (IT)
- University of Cologne (DE)
- Escola Superior de Saúde Egas Moniz (PT)
- Luxembourg Institute of Health (LU)
- Informa (Italy) (IT)
- Hospital de Egas Moniz (PT)
- German Center for Infection Research (DE)
- European Society of Concurrent Enterprising Network (IT)
- Stanford University (US)
Publication Details
- Journal
- Viruses
- Published
- 2024-10-31
- DOI
- https://doi.org/10.3390/v16111715
- Citations
- 4
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- National Institutes of Health